Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Ligand Pharmaceuticals Incorporated

35 indications, side-by-side phase, drug & LoA

$255.54

+0.97 (+0.38%)

B 67Pipeline Score Undervalued Pharma · Commercial
Market Cap
4.60 B
EPS
7.84
P/E Ratio
31.09 $
Value Trade
36.61 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    51.72 M

  • R&D Expenses

    2.15 M

  • Operating CF

    48.69 M

  • Total Assets

    1.53 B

  • Total Liabilities

    534.78 M

  • Equity

    997.32 M

  • D/E Ratio

    12,345

5.85 %
Week
0.57 %
1 Month
23.36 %
3 Month
14.96 %
6 Month
83.83 %
5 Year
194.01 %
All Time
Cash Data
Profitable

  • Cash Position

    779.40 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 8, 2026
Overview
Volume
247.09 K
52 Week Range
98.89 - 247.38
% held by Insiders
2.4 %
% held by Institutions
104.55 %
Enterprise Value
4.27 B
Total Shares
19.67 M
Short %
8.38 %
Float Shares
18.87 M
Company Description
HQ: 3911 SORRENTO VALLEY BLVD, SAN...
Employees:47
https://www.ligand.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
NDA Submission example
Qtorin rapamycin microcystic lymphatic malformations (MLMs)
NDA
—
Biologics
Dermatologic System
Qtorin rapamycin microcystic lymphatic malformations (MLMs)
NDA
—
Biologics
Dermatologic System
Qtorin rapamycin microcystic lymphatic malformations (MLMs)
NDA
—
Biologics
Dermatologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B67
Pipeline Score
$7.9B
Pipeline Value
Undervalued
Valuation Signal
26
Drugs Scored
5.7x
rNPV / MCap
Top 92%
Small Cap
(rank 73 of 905)
Percentile Rank
Ligand Pharmaceuticals Incorporated holds a solid B-grade pipeline (67/100), with $24.2B risk-adjusted pipeline value, led by LGD-6972 in Type 2 Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LGD-6972
Small molecule		Type 2 Diabetes MellitusPhase 2NCT0225022243% $9.1B COMPLETED 252 - -Jun 1, 2015 -Jun 11, 2015
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LGND
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LGND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LGND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LGND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LGND Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LGND Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Ligand Pharmaceuticals Incorporated (LGND) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LGND ranks across every disease it competes in
No competitive intelligence available for LGND.